Patents by Inventor Mark J. Williamson

Mark J. Williamson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7098015
    Abstract: The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: August 29, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kyle J. MacBeth, Joseph M. Carroll, William James Cook, Rachel E. Meyers, Miyoung Chun, Mark J. Williamson
  • Patent number: 7029895
    Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC 17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: April 18, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Mark J. Williamson, Fong-Ying Tsai, Laura A. Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel E. Meyers, Lillian Wei-Ming Chiang, John Joseph Hunter
  • Publication number: 20040157221
    Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 27, 2003
    Publication date: August 12, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rory A. J. Curtis, Thomas Joseph Logan, Maria Alexandra Glucksmann, Rachel E. Meyers, Mark J. Williamson, Laura A. Rudolph-Owen, Miyoung Chun, Fong-Ying Tsai
  • Publication number: 20040058355
    Abstract: The invention provides isolated nucleic acids molecules, designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted.
    Type: Application
    Filed: April 25, 2003
    Publication date: March 25, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, John Joseph Hunter, Rachel E. Meyers, Laura A. Rudolph-Owen, Rory A. J. Curtis, Peter J. Olandt, Fong-Ying Tsai, Katherine M. Galvin, Miyoung Chun, Mark J. Williamson, Inmaculada Silos-Santiago, Rajasekhar Bandaru
  • Publication number: 20040033509
    Abstract: The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted.
    Type: Application
    Filed: February 28, 2003
    Publication date: February 19, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, Mark J. Williamson, Rosana Kapeller-Libermann, Kyle J. MacBeth, John Joseph Hunter, Laura A. Rudolph-Owen, Rajasekhar Bandaru, Fong-Ying Tsai
  • Publication number: 20040009501
    Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 27, 2003
    Publication date: January 15, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rory A. J. Curtis, Thomas Joseph Logan, Maria Alexandra Glucksmann, Rachel E. Meyers, Mark J. Williamson, Laura A. Rudolph-Owen, Miyoung Chun, Fong-Ying Tsai
  • Publication number: 20040009553
    Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC 17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 30, 2003
    Publication date: January 15, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Mark J. Williamson, Fong-Ying Tsai, Laura A. Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel E. Meyers, Lillian Wei-Ming Chiang, John Joseph Hunter
  • Publication number: 20040005685
    Abstract: The invention provides isolated nucleic acids molecules, designated 97316 nucleic acid molecules, which encode novel amine oxidase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 97316 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 97316 gene has been introduced or disrupted. The invention still further provides isolated 97316 proteins, fusion proteins, antigenic peptides and anti-97316 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 3, 2003
    Publication date: January 8, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Peter J. Olandt, Mark J. Williamson
  • Publication number: 20040006016
    Abstract: The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 11, 2003
    Publication date: January 8, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, David White, Keith E. Robison, Kyle J. MacBeth, Joseph M. Carroll, William James Cook, Rachel E. Meyers, Miyoung Chun, Mark J. Williamson
  • Publication number: 20030224417
    Abstract: The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.
    Type: Application
    Filed: March 27, 2003
    Publication date: December 4, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Nadine S. Weich, John Joseph Hunter, David White, Kyle J. MacBeth, Mark J. Williamson, Rachel E. Meyers, Miyoung Chun
  • Publication number: 20030157082
    Abstract: The present invention relates to methods for the diagnosis and treatment of a cancer or cancer. Specifically, the present invention identifies the differential expression of 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480, 20893, 33230, 1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 and 66428 genes in tissues relating to cancer, relative to their expression in normal, or non-cancer disease states, and/or in response to manipulations relevant to a cancer. The present invention describes methods for the diagnostic evaluation and prognosis of various cancers, and for the identification of subjects exhibiting a predisposition to such conditions.
    Type: Application
    Filed: January 30, 2003
    Publication date: August 21, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: John Joseph Hunter, Kyle J. MacBeth, Fong-Ying Tsai, Andrea Lesoon, Eric S. Lightcap, Mark J. Williamson, Laura A. Rudolph-Owen
  • Publication number: 20030153018
    Abstract: The present invention relates to methods for the diagnosis and treatment of a cancer or cancer. Specifically, the present invention identifies the differential expression of 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 genes in tissues relating to cancer, relative to their expression in normal, or non-cancer disease states, and/or in response to manipulations relevant to a cancer. The present invention describes methods for the diagnostic evaluation and prognosis of various cancers, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a cancer or cancer. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cancer.
    Type: Application
    Filed: November 25, 2002
    Publication date: August 14, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: John Joseph Hunter, Mark J. Williamson, Kyle J. MacBeth, Laura A. Rudolph-Owen, Fong-Ying Tsai